Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on the stock and has a $196.00 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Michael Ulz has given his Buy rating due to a combination of factors contributing to Sarepta Therapeutics’ promising outlook. The company has demonstrated strong sales growth for its Elevidys product, with a significant increase in revenue from the previous quarter. This growth is supported by high patient demand, sufficient site capacity, and favorable reimbursement conditions, ensuring broad access to the treatment.
Additionally, Sarepta’s management has expressed confidence by reiterating their sales guidance for 2025, anticipating substantial year-over-year growth. The company is also poised for further success with upcoming catalysts, including data releases from various clinical trials. These factors collectively underpin Michael Ulz’s positive outlook on Sarepta Therapeutics, justifying the Buy rating.
In another report released today, Mizuho Securities also maintained a Buy rating on the stock with a $190.00 price target.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year.